US 12,442,820 B2
Peripheral blood biomarker for evaluating anti-tumor immune effect of radiation therapy
Hiroshi Kagamu, Saitama (JP)
Assigned to Saitama Medical University, Saitama (JP)
Appl. No. 17/432,744
Filed by Saitama Medical University, Saitama (JP)
PCT Filed Feb. 19, 2020, PCT No. PCT/JP2020/006616
§ 371(c)(1), (2) Date Aug. 20, 2021,
PCT Pub. No. WO2020/171138, PCT Pub. Date Aug. 27, 2020.
Claims priority of application No. 2019-028502 (JP), filed on Feb. 20, 2019; and application No. 2019-175852 (JP), filed on Sep. 26, 2019.
Prior Publication US 2022/0107324 A1, Apr. 7, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/574 (2006.01); G01N 33/569 (2006.01)
CPC G01N 33/57492 (2013.01) [G01N 33/56972 (2013.01); G01N 2333/70514 (2013.01); G01N 2333/70517 (2013.01); G01N 2333/70521 (2013.01); G01N 2333/70553 (2013.01); G01N 2333/70564 (2013.01); G01N 2333/70589 (2013.01)] 18 Claims
 
1. A method of using a composition of a cell subpopulation in a sample obtained from a subject who has undergone radiation therapy as an indicator of radiation therapy-induced immune activation in the subject, comprising:
analyzing the composition of the cell subpopulation in the sample obtained from the subject;
wherein the presence/absence of immune activation in the subject is indicated by comparing an amount of a CD4+ T cell subpopulation correlated with dendritic cell stimulation in an antitumor immune response in the sample with a baseline, and the CD4+ T cell subpopulation correlated with dendritic cell stimulation in an antitumor immune response is a cell subpopulation within a CD62LlowCD4+ T cell population,
wherein an increase in the amount of the cell subpopulation in the sample relative to the baseline indicates that immunity is activated by radiation therapy in the subject,
wherein no increase in the amount of the cell subpopulation in the sample relative to the baseline indicates that immunity is not activated by radiation therapy in the subject,
wherein radiation therapy-induced immune activation in the subject further indicates that cancer immunotherapy comprising one or more immune checkpoint inhibitors should be administered to the subject at that point in time,
wherein the one or more immune checkpoint inhibitors comprise a PD-1 inhibitor, a PD-L1 inhibitor, and/or a CTLA-4 inhibitor, and
wherein no radiation therapy-induced immune activation in the subject further indicates that radiation therapy should be re-administered to the subject.